Intensity Therapeutics Announces New Clinical Data in Solid Tumors for its Lead Asset, INT230-6
New data from the combination of INT230-6 with ipilimumab
New data from the combination of INT230-6 alone or with pembrolizumab
First data from the Phase 2 INVINCIBLE study in early-stage breast cancer
WESTPORT, Conn., May 3, 2022 /PRNewswire/ --Intensity Therapeutics, Inc. ("Intensity"), a clinical-stage biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced that phase 2 sarcoma data, phase 2 breast cancer data and phase 1/2 solid tumor data from its ongoing cohort studies of lead asset, INT230-6, will be presented in two oral and three poster sessions at the upcoming 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, being held live at McCormick Place in Chicago, IL, and online, from June 3-7, 2022.
Abstract Title: INT230-6 monotherapy and in combination with ipilimumab (IPI) across a broad spectrum of refractory soft tissue sarcomas (STS) [Intensity IT-01; BMS#CA184-592].
Abstract Title: Effect of intratumoral INT230-6 on tumor necrosis and promotion of a systemic immune response: Results from a multicenter phase 1/2 study of solid tumors with and without pembrolizumab (PEM) [Intensity IT-01; Merck KEYNOTE-A10].
Abstract Title: Intratumoral (IT) INT230-6 can cause tumor necrosis In Vivo: Preliminary results of a phase II randomized presurgical window-of-opportunity study in early breast cancers (the INVINCIBLE study).
Copies of these materials will also be available on the Intensity Therapeutics website at https://intensitytherapeutics.com/events following completion of the live presentation.
INT230-6 is currently being evaluated in several phase 2 cohorts (NCT03058289) in patients with various advanced solid tumors as part of Study IT-01. In 2019, the Company signed a clinical collaboration agreement with Merck Sharpe & Dohme (Merck) to evaluate the combination of INT230-6 and KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 (programmed death receptor-1) therapy, in patients with advanced pancreatic, colon, squamous cell and bile duct malignancies. In 2020, the Company executed a clinical collaboration agreement with Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Bristol-Myers Squibb's anti-CTLA-4 antibody, Yervoy® (ipilimumab), in patients with advanced liver, breast and sarcoma cancers. In 2021, the Company executed agreements with the Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase 2 study in women with early stage breast cancer (the INVINCIBLE study) (NCT04781725).
About Intensity Therapeutics
Investor Relations Contact:
US Media Contact:
View original content:https://www.prnewswire.com/news-releases/intensity-therapeutics-announces-new-clinical-data-in-solid-tumors-for-its-lead-asset-int230-6-were-accepted-for-two-poster-discussion-sessions-and-three-poster-presentations-at-the-upcoming-2022-american-society-of-clinical-onc-301537143.html
SOURCE Intensity Therapeutics, Inc.